Clinical Research Directory
Browse clinical research sites, groups, and studies.
Effect of Roflumilast and Desloratadine as Add-On Therapy in Patients With Rheumatoid Arthritis
Sponsor: Horus University
Summary
Rheumatoid arthritis is a chronic inflammatory disease that causes joint pain, swelling, and disability. Although standard disease-modifying antirheumatic drugs (DMARDs) are effective for many patients, some individuals continue to experience active disease and inflammation. The aim of this study is to evaluate the effectiveness and safety of adding either roflumilast or desloratadine to standard DMARD therapy in patients with rheumatoid arthritis. Participants will be randomly assigned to receive either roflumilast, desloratadine, or placebo in addition to their usual treatment. The study will assess changes in disease activity, inflammatory biomarkers, and patient-reported outcomes over a three-month follow-up period. The results of this study may help identify new add-on treatment options to improve disease control in patients with rheumatoid arthritis.
Official title: Clinical Study to Compare the Possible Efficacy and Safety of Roflumilast and Desloratadine as Adjuvant Therapy for Rheumatoid Arthritis
Key Details
Gender
All
Age Range
18 Years - 60 Years
Study Type
INTERVENTIONAL
Enrollment
90
Start Date
2026-04-23
Completion Date
2027-07
Last Updated
2026-05-12
Healthy Volunteers
No
Conditions
Interventions
Roflumilast
Roflumilast administered orally as add-on therapy to standard disease-modifying antirheumatic drugs
Desloratadine
Desloratadine administered orally as add-on therapy to standard disease-modifying antirheumatic drugs.
Placebo
Matching placebo administered orally as add-on therapy to standard disease-modifying antirheumatic drugs.
Locations (1)
Faculty of Pharmacy, Horus University in Egypt
Damietta, Damietta Governorate, Egypt